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Concurrent chemoradiotherapy (CT+RT) 
is a standard of care for good-performance 
patients with unresectable stage IIIA/IIIB 
non-small cell lung cancer (NSCLC).1 2 In a 
phase II study, treatment with two cycles of 
pemetrexed-cisplatin (Pem-Cis) induction, 
followed by full-dose Pem-Cis plus concur-
rent RT was well tolerated and effective in 90 
patients with stage IIIA/IIIB unresectable, 
non-squamous NSCLC.3 Here, we report by-age 
subgroup data for 17 elderly (aged >70 years) 
and 73 non-elderly patients (aged ≤70 years).
The Eastern Cooperative Oncology Group 
performance status 0–1, no prior systemic 
therapy, adequate pulmonary function 
(FEV1 >50% and carbon monoxide diffusing 
capacity (DLCO) >40% of predicted normal 
value) and a total lung volume to receive 
at least 20 Gy (V20) of ≤35% were required 
(patient characteristics: see online supple-
mentary material). Patients received two 
3-week cycles of Pem 500 mg/m2 and Cis 
75 mg/m2 as per PEM label (vitamin supple-
mentation). Patients with complete response 
(CR), partial response or stable disease were 
then eligible for concurrent CT+RT, which 
included two additional cycles of full-dose 
Pem-Cis CT and RT (66 Gy, 33 fractions).
Of 17 elderly patients, 16 (94.1%) 
started concurrent CT+RT and 12 (70.6%) 
completed CT+RT as planned. Of 73 non-el-
derly patients, 59 (80.8%) started concurrent 
CT+RT and 52 (71.2%) completed CT+RT as 
planned.
The regimen was effective both in the 
elderly and non-elderly patient subgroups, 
with 1-year progression-free survival rates of 
53.3% and 44.9% and median overall survival 
times of 25.1 and 26.2 months, respectively 
(figure 1). Two elderly patients achieved CR. 
In one patient, the tumour became amenable 
to surgical resection after CT+RT, response 
was classified as CR after surgery, the other 
achieved CR after CT+RT alone. Overall 
response and disease control rates in this 
subgroup were 64.7% and 94.1%, respectively 
(non-elderly: 58.9% and 74.0%).
During concurrent CT+RT, 8 of the 16 
elderly patients who started CT+RT (50.0%) 
had grade (G)3/4 treatment-emergent 
adverse events (TEAEs; non-elderly: 25 of 
59, 42.4%; details in online supplementary 
material). No elderly patient died due to 
drug toxicity, none required transfusions. 
Neutropaenia and leucopenia were the most 
frequent haematologic toxicities, oesopha-
gitis and dysphagia were the most common 
non-haematologic toxicities; 18.8% of the 
elderly patients had G3 oesophagitis, none 
had febrile neutropaenia or G3/4 radiation 
dermatitis/mucositis, G3/4 radiation pneu-
monitis, G3/4 dehydration or diarrhoea.
These data align with results from the 
overall study population,3 suggesting that 
this regimen is feasible in elderly and 
non-elderly patients alike and may help in 
making the disease surgically resectable in 
elderly patients with good performance. 
Findings should be interpreted with caution 
due to the exploratory nature and small 
number of elderly patients included. Never-
theless, to our knowledge, these are the first 
data for elderly patients receiving Pem-Cis 
induction followed by Pem-Cis and concur-
rent RT. The data suggest that fit elderly 
patients may tolerate concurrent CT+RT 
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and stand to gain survival benefits. The data provide 
a rationale for conducting more prospective studies 
in elderly patients with locally advanced NSCLC that 
may help to develop evidence-based recommendations 
to improve management of these patients. Until more 
evidence is generated, performance status and comor-
bidities should predominate over age alone with respect 
to decision-making.4
Figure 1 Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. CI, confidence interval; m, 
median; N, number of all patients; n, number of patients with event; n.e., not estimable; OS, overall survival; PD, progressive 
disease; PFS, progression-free survival. Circles indicate censored patients.
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